Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.
Location: United States, Massachusetts, Lexington
Employees: 11-50
Total raised: $178M
Founded date: 2017
Investors 6
| Date | Name | Website |
| - | The Column... | thecolumng... |
| - | Droia Onco... | droiaventu... |
| - | Timefolio ... | timefolioc... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Atlas Vent... | atlasventu... |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.01.2024 | Series C | $75M | - |
| 24.04.2020 | Series B | $63M | - |
| 23.05.2018 | Series A | $40M | - |
Mentions in press and media 16
| Date | Title | Description | Source |
| 23.01.2024 | Accent Therapeutics Raises $75M in Series C Funding | Accent Therapeutics, a Lexington, MA-based biopharmaceutical company focused on small molecule preci... | finsmes.co... |
| 27.02.2023 | Accent Therapeutics upgrades to Xavo R3 for their small mole... | Xavo, a leading provider of Software-as-a-Service for Biopharma R&D announces that Accent Therap... | einpresswi... |
| 29.04.2021 | ALDEYRA THERAPEUTICS, INC. Aldeyra Therapeutics, Inc. : Ann... | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused ... | marketscre... |
| 27.04.2021 | ALDEYRA THERAPEUTICS, INC. Aldeyra Therapeutics, Inc. : Ann... | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused ... | marketscre... |
| 01.07.2020 | June VC Funding: 65 startups raise over $2.2B with agtech, b... | It is summer for Boston startups indeed. More than 60 startups raised over $2 billion in venture fun... | bizjournal... |
| 24.04.2020 | Accent Therapeutics Completes $63M Series B Financing | Accent Therapeutics, a Lexington, MA-based biopharmaceutical company developing breakthrough treatme... | finsmes.co... |
| 24.04.2020 | Cancer Therapy Company Accent Therapeutics Raises $63 Millio... | Biopharmaceutical company Accent Therapeutics announced it has raised $63 million in Series B fundin... | pulse2.com... |
| 23.04.2020 | Accent Therapeutics Announces $63 Million Series B | LEXINGTON, Mass.--(BUSINESS WIRE)--Accent Therapeutics, a biopharmaceutical company developing break... | citybizlis... |
| 23.04.2020 | Accent Therapeutics nabs $63M for RNA cancer push | Two years ago, Accent Therapeutics got off a $40 million series A to target RNA-modifying proteins i... | fiercebiot... |
| 23.04.2020 | It's not developing drugs that bind to RNA, or morphing... | First came the concept of epigenetics, the study of chemical modifications made to the blu... | endpts.com... |
Show more